期刊
DRUG DELIVERY
卷 25, 期 1, 页码 679-689出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/10717544.2018.1440666
关键词
Prostate cancer; gene therapy; dendrimer; lactoferrin; nanoparticles
资金
- Worldwide Cancer Research [16-1303]
- Saudi Cultural Bureau (Kingdom of Saudi Arabia) [15678]
- Princess Nourah bint Abdulrahman University (Kingdom of Saudi Arabia) [15678]
- Dunhill Medical Trust [R463/0216]
- Association for International Cancer Research
- UK Research Partnership Institute Fund (UKRPIF)
- Cancer Research UK [22904] Funding Source: researchfish
- The Dunhill Medical Trust [R463/0216] Funding Source: researchfish
The possibility of using gene therapy for the treatment of prostate cancer is limited by the lack of intravenously administered delivery systems able to safely and selectively deliver therapeutic genes to tumors. Given that lactoferrin (Lf) receptors are overexpressed on prostate cancer cells, we hypothesized that the conjugation of Lf to generation 3-diaminobutyric polypropylenimine dendrimer would improve its transfection and therapeutic efficacy in prostate cancer cells. In this study, we demonstrated that the intravenous administration of Lf-bearing DAB dendriplexes encoding TNF resulted in the complete suppression of 70% of PC-3 and 50% of DU145 tumors over one month. Treatment with DAB-Lf dendriplex encoding TRAIL led to tumor suppression of 40% of PC-3 tumors and 20% of DU145 tumors. The treatment was well tolerated by the animals. Lf-bearing generation 3-polypropylenimine dendrimer is therefore a highly promising delivery system for non-viral gene therapy of prostate cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据